Home > Drugs A – Z > Ofatumumab (By injection)

Ofatumumab (By injection)

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Ofatumumab injection is used in combination with chlorambucil to treat a type of cancer of the white blood cells called chronic lymphocytic leukemia (CLL) in patients who have not received any treatments in the past. It is also used in combination with fludarabine and cyclophosphamide to treat patients with relapsed CLL. This medicine is also used in patients with CLL who have already been… Read more
Brand names include
Arzerra
Drug classes About this
Antineoplastic Agent, Immunological Agent

What works? Research summarized

Evidence reviews

The role of the monoclonal anti‐CD20 antibodies for treatment of patients with chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) is a malignant disease and accounts for 25% of all leukaemias. The disease is the most common lymphoid malignancy in western countries, and is characterised by a highly variable clinical course and prognosis. Some patients may have minimal or no symptoms for many years with a normal life expectancy, without requiring treatment. Other people are symptomatic at diagnosis or soon thereafter and can experience infectious and autoimmune complications, leading to a reduced lifespan. Standard treatment includes chemotherapy with one or more agents. Presently monoclonal antibodies are added, especially alemtuzumab and rituximab. However, the impact of these agents remains unclear, as there have been hints for increased overall survival, but also for an increased risk of severe infections in non‐randomised trials. In this systematic review we summarised and analysed the evidence from randomised controlled trials on efficacy and safety of monoclonal anti‐CD20 antibodies (such as rituximab and ofatumumab) in the treatment of CLL. We searched medical databases, such as EMBASE, MEDLINE and CENTRAL, and found seven randomised controlled trials fulfilling our inclusion criteria. Included trials compared anti‐CD20 antibodies, particularly rituximab, to no further therapy or compared to anti‐cancer therapy in CLL, irrespective of whether the patients were newly diagnosed or relapsed patients. Only five of the seven identified trials could be included in one of the two performed meta‐analyses.

Addendum to Haematological Cancers: Improving Outcomes (Update)

Different levels of service are needed to manage haematological cancers, depending on the particular cancer in question. Because of the increased complexity of care and changes in the levels of care from those specified in the 2003 NICE cancer service guidance on improving outcomes in haematological cancers, an update was needed.

Systematic review of the psychological consequences of false-positive screening mammograms

Study found that the experience of having a false-positive screening mammogram can cause breast cancer-specific psychological distress, that may endure for up to 3 years and reduce the liklihood of returning for screening the next time

See all (5)

Summaries for consumers

The role of the monoclonal anti‐CD20 antibodies for treatment of patients with chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) is a malignant disease and accounts for 25% of all leukaemias. The disease is the most common lymphoid malignancy in western countries, and is characterised by a highly variable clinical course and prognosis. Some patients may have minimal or no symptoms for many years with a normal life expectancy, without requiring treatment. Other people are symptomatic at diagnosis or soon thereafter and can experience infectious and autoimmune complications, leading to a reduced lifespan. Standard treatment includes chemotherapy with one or more agents. Presently monoclonal antibodies are added, especially alemtuzumab and rituximab. However, the impact of these agents remains unclear, as there have been hints for increased overall survival, but also for an increased risk of severe infections in non‐randomised trials. In this systematic review we summarised and analysed the evidence from randomised controlled trials on efficacy and safety of monoclonal anti‐CD20 antibodies (such as rituximab and ofatumumab) in the treatment of CLL. We searched medical databases, such as EMBASE, MEDLINE and CENTRAL, and found seven randomised controlled trials fulfilling our inclusion criteria. Included trials compared anti‐CD20 antibodies, particularly rituximab, to no further therapy or compared to anti‐cancer therapy in CLL, irrespective of whether the patients were newly diagnosed or relapsed patients. Only five of the seven identified trials could be included in one of the two performed meta‐analyses.

Ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL): Ibrutinib (Imbruvica) as monotherapy for people who have had treatment for CLL and are unable to have further chemotherapy

In 2016, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed the advantages and disadvantages of ibrutinib (trade name: Imbruvica) for people who have had treatment for chronic lymphocytic leukemia (CLL) and are unable to have chemotherapy. The manufacturer provided one study involving about 391 people. 196 people had treatment with the standard therapy ofatumumab, while 195 people received ibrutinib. In addition, all participants received best supportive care (BSC).

Idelalisib (Zydelig) for chronic lymphocytic leukemia (CLL): Overview

Idelalisib (trade name: Zydelig) has been approved in Germany since September 2014 for the treatment of chronic lymphocytic leukemia (CLL) in adults.

PubMed Health Blog...

read all...